Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro
Authors
Keywords
Age related macular degeneration, Choroidal neovascularization, VEGF, PDGF
Journal
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Volume 255, Issue 5, Pages 963-972
Publisher
Springer Nature
Online
2017-02-04
DOI
10.1007/s00417-017-3595-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
- (2016) Anand Giddabasappa et al. EXPERIMENTAL EYE RESEARCH
- Molecular mechanisms of subretinal fibrosis in age-related macular degeneration
- (2016) Keijiro Ishikawa et al. EXPERIMENTAL EYE RESEARCH
- A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration
- (2016) Glenn J. Jaffe et al. OPHTHALMOLOGY
- Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
- (2014) Robert L Avery et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Ranibizumab Treatment in Age-Related Macular Degeneration: A Meta-Analysis of One-Year Results
- (2014) H. Gerding KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
- (2014) Wan Ling Wong et al. Lancet Global Health
- Subfoveal Fibrosis in Eyes With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab
- (2013) Sara Brandi Bloch et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Aflibercept Therapy for Exudative Age-related Macular Degeneration Resistant to Bevacizumab and Ranibizumab
- (2013) Benjamin Bakall et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
- (2013) Robert L Avery BRITISH JOURNAL OF OPHTHALMOLOGY
- Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration
- (2013) Ilse Krebs et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Multikinase-Inhibitoren als therapeutischer Ansatz bei neovaskulärer AMD: In-vitro-Evaluation der Sicherheit von Axitinib, Pazopanib und Sorafenib zur intraokularen Anwendung
- (2013) S. Thiele et al. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
- Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
- (2013) Soraya Rofagha et al. OPHTHALMOLOGY
- Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
- (2013) Ebenezer Daniel et al. OPHTHALMOLOGY
- INTRAOCULAR GROWTH FACTORS AND CYTOKINES IN PATIENTS WITH DRY AND NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
- (2013) Philipp S. Muether et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Antiangiogenic Effects of Axitinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase, on Laser-Induced Choroidal Neovascularization in Mice
- (2012) Seungbum Kang et al. CURRENT EYE RESEARCH
- Novel insights into pericyte–myofibroblast transition and therapeutic targets in renal fibrosis
- (2012) Fan-Chi Chang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression
- (2011) M. Franco et al. BLOOD
- Basic and Therapeutic Aspects of Angiogenesis
- (2011) Michael Potente et al. CELL
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors
- (2011) B. I. Rini et al. CLINICAL CANCER RESEARCH
- Axitinib modulates hypoxia-induced blood–retina barrier permeability and expression of growth factors
- (2011) Marcus Kernt et al. GROWTH FACTORS
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23 27 24 clusters
- (2011) Q. Zhou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endothelial-Mural Cell Signaling in Vascular Development and Angiogenesis
- (2009) Konstantin Gaengel et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells
- (2008) Ângela Carneiro et al. EXPERIMENTAL EYE RESEARCH
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started